Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stop-Flu-2: Influenza Vaccine vs Zanamivir Prophylaxis
NCT00784784Phase 3Completed
- Sponsor
- Mount Sinai Hospital
- Start
- Nov 2008
- Primary completion
- May 2009
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zanamivir and influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated) in influenza (2 arms), sponsored by Mount Sinai Hospital. Primary endpoint: Number of Laboratory Confirmed Influenza Infections at 6 months. Started Nov 2008; status: completed.
02
Drugs
zanamivirinfluenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (formaldehyde inactivated)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00784784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00784784.